Skip to content
value.today

Predictive Therapeutics Ltd.

🇮🇱 Rehovot, Israel, IsraelBiotechnologyFounded 2014
Total raised
$56 M
3 rounds on record
Latest round
$38 M
Sep 2019
First round on record
Nov 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Predictive Therapeutics Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2022$45 MIssued in a merger or acquisition$10 to $50 million

Predictive Therapeutics Ltd.: Private sale, May 2022

Investors in this round

0 investors had bought by the notice of May 24, 2022: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Bermuda

People named in the notice

  • Asher Nathan · Executive Officer, Director · CEO and Director
  • Robert Harow · Executive Officer, Director · CFO, COO and Director
  • J. Tomilson Hill · Director
  • Paul Marinelli · Director
  • Roger Kornberg · Director
  • Seo-Yong Tomilson Cho · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount represents the deemed value of Issuer's shares issued to InterX, Inc. shareholders in a merger, consisting of $4.7 million of common shares issued at closing, and $40 million of preferred shares to be issued post-closing.”

Signed by Robert Harow, Director, CFO and COO. Source: SEC Form D, newest notice filed May 24, 2022. Read the notice at the SEC.

equity, optionsSEC
Sep 2019$38 MNo. 3$10 to $50 million

Predictive Therapeutics Ltd.: Raise no. 3, Sep 2019

Investors in this round

48 investors had bought by the notice of Oct 23, 2019: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $45 M offered; $7 M still to sell
Smallest investment taken
$13,900
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$902,857
Finders' fees
$80,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Bermuda

People named in the notice

  • Robert Harow · Executive Officer, Director
  • Asher Nathan · Director · Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive an

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Bradley Woods & Co. Ltd. (CRD 13660) · broker-dealer Eric Singer (CRD 718955) · New York, New YorkSold in CA, CO, CT, DE, FL, GA, IL, MA, MD, NC, NJ, NY, PA, TX

Remarks in the notice

  • On fees: “In addition the finder received 42,993 warrants as consideration”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Robert Harow, Cfo. Source: SEC Form D, newest notice filed Oct 23, 2019. Read the notice at the SEC.

equitySEC
Jun 2017$9 MNo. 2$2 to $10 million

Predictive Therapeutics Ltd.: Raise no. 2, Jun 2017

Investors in this round

20 investors had bought by the notice of Dec 18, 2018: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$650,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Bermuda

People named in the notice

  • Robert Harow · Executive Officer, Director
  • Asher Nathan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Bradley Woods & Co. Ltd. (CRD 13660) · broker-dealer Eric Singer (CRD 718955) · New York, New YorkSold in CA, CT, MA, MD, NJ, NY

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Robert Harow, Cfo. Source: SEC Form D, newest notice filed Dec 18, 2018. Read the notice at the SEC.

equitySEC
Nov 2014$9 MNo. 1$2 to $10 million

Predictive Therapeutics Ltd.: Raise no. 1, Nov 2014

Investors in this round

50 investors had bought by the notice of Aug 21, 2019: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $18 M offered; $9 M still to sell
Smallest investment taken
$17,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
$630,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Bermuda

People named in the notice

  • Robert Harow · Executive Officer, Director
  • Asher Nathan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • First Liberties Securities (CRD 14432) · broker-dealer Eric Singer (CRD 718955) · New York, New YorkSold in DE, FL, IL, MA, MD, NJ, NY, TX
  • Bradley Woods & Co. Ltd. (CRD 13660) · broker-dealer Eric Singer (CRD 718955) · New York, New YorkSold in FL, IL, MA, MD, NJ, NY, TX

Remarks in the notice

  • On the amounts: “The Total Amount Sold includes the amount was reported in the original filing ($2,493,856). The Remaining to be sold amount includes the exercise price for the shares underlying the warrants issued.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Robert Harow, Cfo. Source: SEC Form D and 1 amendment, newest notice filed Aug 21, 2019. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Predictive Therapeutics Ltd. chose not to state its revenue in its newest notice of a funding round (May 2022).

    SEC Form D · May 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2022

That is all the official record says: Predictive Therapeutics Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Predictive Therapeutics Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Predictive Therapeutics Ltd.
NameRoleNamed in
Asher NathanCEO and DirectorMay 2022
Robert HarowCFO, COO and DirectorMay 2022
Asher NathanCEO and DirectorMay 2022
J. Tomilson HillDirectorMay 2022
Paul MarinelliDirectorMay 2022
Robert HarowCFO, COO and DirectorMay 2022
Roger KornbergDirectorMay 2022
Seo-Yong Tomilson ChoDirectorMay 2022